関連する実験動画
Updated: Sep 9, 2025

05:49
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
Published on: May 5, 2021
5.0K
メトホルミンは,レバルの遺伝性視神経病の進行を変化させる可能性がある:症例報告
Shenoda Abd Elmaseh1, Danielle A Gauthier1,2, Maryam Golmohammadi1,2
1Department of Ophthalmology, David Geffen School of Medicine, Los Angeles, CA, United States.
Frontiers in medicine
|September 4, 2025
まとめ
メトホルミンはレバーの視力を改善しました.
科学分野:
- ミトコンドリア遺伝学と 神経眼科学
- 遺伝性視神経病を研究しています
- 視力障害に対する新しい治療法を模索しています
背景:
- レベルの遺伝性視神経病 (LHON) は,母から受け継がれるミトコンドリアDNA (mtDNA) 疾患である.
- 主に若い男性に発症する 漸進的な双方の視力低下が特徴です
- アイデベノンのような 現在の治療法は ミトコンドリアの機能や視力の改善に わずかな効果があります
研究 の 目的:
- 女性患者のLHON管理のユニークなケースを報告します.
- 標準治療に反応しない患者におけるメトホルミンの有効性を調べる.
- LHONにおけるメトホルミンの役割に関するさらなる研究の必要性を強調する.
主な方法:
- LHON (m.11778G>A/MT-ND4) と2型糖尿病と診断された48歳の女性のケース研究.
- アイデベノン,NAD+,HRTを含む治療にも関わらず,26ヶ月間にわたって進行的な視力低下が記録されています.
- メトフォーミン治療を開始した後の視野の変化をモニターする.
主要な成果:
- 26ヶ月の漸進的な視力低下の後,患者の視野は有意に改善しました.
- この改善は,イデベノン,NAD+,およびHRTの失敗後のメトフォーミン治療で起こりました.
- このケースは,特に複雑な症例において,LHONの管理におけるメトホルミンの潜在的な利点を示唆しています.
結論:
- メトフォーミンは,他の治療に反応しないLHON患者の視野を改善する潜在的有効性を示しました.
- このケースは,LHONの代替管理戦略について興味深い視点を提供します.
- LHONにおけるメトホルミンのメカニズムを理解するために,さらなる分子および臨床試験が不可欠です.
関連する概念動画
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Open Angle Glaucoma: Treatment
554
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
554
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
Photoreceptors and Visual Pathways
6.5K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.5K
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256

